SLN: Silence Therapeutics Inc. Price to Sales
Silence Therapeutics develops RNA-based drugs to block pathogenic liver proteins. The price-to-sales ratio demonstrates the market valuation of the asset, where the 2675.50 mark indicates the current consensus value. Stability ensures the sector's independence from macroeconomics, while business resilience is bolstered by strict bioethical compliance and the minimization of chemical waste during the creation of genetic medicines.
Analytical breakdowns for Silence Therapeutics PLC (SLN)
- share price and consensus valuation forecast:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Silence Therapeutics|SLN - Long-Term Debt to Capital|Current Liabilities to Capital Silence Therapeutics plc|SLN - Company Total Debt|Debts to Book Capitalization Silence Therapeutics plc|SLN - Company Long-Term Liabilities|Amount of Current Liabilities Silence Therapeutics|Interim Coverage Ratio silence-therapeutics.com
- earnings and valuation multiples information:
SLN - Net Profit|Future Profit Silence Therapeutics|SLN - Price to Earnings Ratio|Market Cap to Projected Earnings Silence Therapeutics Corp|SLN - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Silence Therapeutics|SLN - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Silence Therapeutics|SLN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months silence-therapeutics.com|SLN - Earnings growth in current year|Projected earnings per share growth rate for next year Silence Therapeutics
- issuer revenue and sales details:
Summary company analytics:SLN Silence Therapeutics Inc.
Positive sentiment stemming from the success of the small interfering RNA platform in combating cardiovascular pathologies directly impacts the market value of Silence Therapeutics (SLN). The company's price-to-sales ratio reflects the current market valuation of the business relative to its actual cash flows, where any deviation of this metric from average values signals either an overvalued asset or the potential for a reversion to the median.
Who Silence Therapeutics competes with
TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Revenue Ratio|10x Genomics Inc - Market Cap to Revenue|NTLA (Intellia Therapeutics, Inc.) - Price-to-Sales Ratio|Stoke Corp - P/S Multiple|BLFS (BioLife) - Market Cap to Revenue Ratio|wavelifesciences.com (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics, Inc.) - P/S Multiple|Market Cap to Revenue Prime Medicine Corp (PRME)|P/S Multiple TSHA|P/S Multiple uniQure N.V. (QURE)|Price-to-Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc - P/S Multiple|OCGN - P/S Multiple|PACB: P/S Multiple|BNTC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Design Therapeutics, Inc.|RCKT: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Revenue Ratio|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio
